# US 2007/0031444 A1 · Compounds targeted to cellular locations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2007/0031444 A1
- Document ID: US20070031444A1
- Status: Published application
- Kind: A1
- Application number: 11/427,112
- Filed: 2006-06-28
- Published: 2007-02-08
- Earliest claimed: 2000-07-07
- Assignees: AdProTech Limited
- Inventors: Pamela Rowling; Geoffrey Smith; Simon Ridley
- Web page: https://patentgrep.com/patent/US20070031444A1

## CPC

- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A soluble derivative of a soluble polypeptide, which comprises two or more heterologous membrane binding elements with low membrane affinity covalently associated with the polypeptide, the elements being soluble in aqueous solution, and the elements being capable of interacting, independently and with themodynamic additivity, with components of cellular or artificial membranes exposed to extracellular fluids, characterized in that the membrane binding elements target lipid raft components of the membrane and bind to the lipid rafts to localize the polypeptide at the lipid rafts.

## Claims

### Claim 1

A compound comprising a membrane binding peptide, wherein the peptide is modified by the addition of a C-terminal cysteine residue, wherein the C-terminal cysteine residue is covalently associated with a fluorescein derivative which is covalently associated through a S-5-succinimido group, and wherein the compound is selected from the group consisting of:
a) N-Myristoyl-Gly-Ser-Ser-Lys-Ser-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-Pro-Gly-Glu-Cys(S-5-succinimido fluorescein)-NH2 (APT2087) (SEQ ID NO: 13),
b) N-Myristoyl-Gly-Ser-Ser-Lys-Ser-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-Pro-Gly-Glu-Cys(S-5-succinimido Alexafluor™488 C5)-NH2 (APT2104) (SEQ ID NO: 14), and
c) N-Myristoyl-Gly-Ser-Ser-Lys-Ser-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-Pro-Gly-Glu-Cys(S-5-succinimido Alexafluor™546 C5)-NH2 (APT2105) (SEQ ID NO: 15).

### Claim 2 (depends on 1)

The compound of claim 1 interacts selectively with components of lipid rafts.

### Claim 3 (depends on 2)

The compound according to claim 2, in which the components of lipid rafts include one or more of phosphatidylserine, phosphatidyl glycerol, glycosphingolipids, cholesterol, GPI-anchored proteins associated with lipid rafts, and other protein components of lipid rafts that may be found normally on the exoplasmic face of the cell.

### Claim 4 (depends on 1)

The compound of claim 1 modulates the function of the lipid rafts either to affect intracellular signaling or to change extracellular functions mediated through the raft domains.

### Claim 5 (depends on 1)

The compound of claim 1 mediates internalization of the peptide.

### Claim 6 (depends on 1)

The compound of claim 1 wherein the peptide is a soluble complement regulatory molecule, including but not restricted to CD59 and DAF, which is targeted to lipid rafts and the signaling pathways that are associated with lipid rafts.

### Claim 7 (depends on 6)

The compound according to claim 6 wherein the soluble complement regulatory molecule is a modified CD59 or DAF peptide, which is targeted to lipid rafts.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein the modified CD59 or DAF peptide is selected from the group consisting of:
APT635 (Seq ID No. 5),
APT2063 (Seq ID No. 8),
APT530 (Seq ID No. 10 ),
APT2334 (Seq ID No. 11),
APT070, and
APT154.

### Claim 9 (depends on 1)

The compound of claim 1 further comprises a derivatised antibody, or antibody fragment which can provide a surrogate receptor localized at a lipid raft to divert a mediator interacting with a lipid raft receptor or which can neutralise a further component of a raft such as a cofator required for signaling.

### Claim 10 (depends on 1)

The compound of claim 1 further comprises a derivated chemical or biological entity that possesses the physical property of fluorescence which enables lipid rafts to be identified and/or monitored.

### Claim 11 (depends on 1)

The compound of claim 1 further comprises a derivatised chemical or biological entity involved in a catalytic process either as an enzyme an enzyme substrate or an enzyme inhibitor.

### Claim 12 (depends on 1)

The compound of claim 1 further comprises a derivatised chemical or biological entity that can form a covalent chemical bond with proteins, sugar groups or lipids that are localized in lipid rafts thus permitting the isolation and identification of the raft component.

### Claim 13 (depends on 12)

The compound according to claim 12, wherein said entity contains photo-, chemo-, or enzyme-activated crosslinking groups.

### Claim 14 (depends on 1)

A process for preparing a compound of claim 1, wherein the process comprises expressing DNA encoding the peptide portion of the compound in a recombinant host cell and recovering the product and thereafter post translationally modifying the polypeptide to chemically introduce membrane binding elements with selectivity for lipid rafts.

### Claim 15 (depends on 14)

The process according to claim 14, wherein the process comprises the steps of:
i) preparing a replicable expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said polypeptide portion;
ii) transforming a host cell with said vector;
iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said polypeptide; and
iv) recovering said polypeptide.

### Claim at position 16

16-19. (canceled)

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 18

21-22. (canceled)
